قالب وردپرس درنا توس
Home / Health / Regeneron’s Covid-19 antibody drug suspends trial in patients in the sickest hospital

Regeneron’s Covid-19 antibody drug suspends trial in patients in the sickest hospital



Due to safety considerations, Regeneron Pharmaceuticals Inc. suspended Covid-19 antibody drug testing for the most sickly hospitalized patients. This is the latest setback for antibody drug testing for patients with the most advanced disease.

Regeneron said on Friday that it is suspending the registration of Covid-19 hospitalized patients undergoing mechanical ventilation or high-flow oxygen hospitalization, after an independent monitoring committee observed “currently there are potential safety signals and adverse risks/benefits”.

The committee recommends that the enrollment of these patients be suspended until more data is collected and analyzed.

This will not affect other tests of antibody drugs, as demonstrated in another trial to reduce virus levels and doctor visits. Currently, the drug and Eli Lilly & Co.

Regeneron̵

7;s research will continue to recruit hospitalized patients who receive little or no oxygen support, and their condition is milder than those who require large amounts of oxygen or mechanical respiratory assistance. The company said that the risks and benefits for hospitalized patients with milder illnesses are still acceptable.


Source link